DRKS00012634已完成不适用
A postmarketing surveillance with the short stem uncemented Endprosthesis (optimys)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 879
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •Patient shall:
- •suffer from primary or secondary coxarthrosis. One or more of the following pathologies/symptoms: coxarthrosis, dysplastic coxarthrosis, rheumatoid arthritis, necrosis of the head of the femur or posttraumatic coxarthrosis.
- •Be ready to participate in the follow-up examinations mentioned above
- •Be between 18 and 85 years old at the time of inclusion
- •Be a candidate for a primary implantation of a hip endoprosthesis
- •Be expected to recover completely
- •Additional inclusion criteria for sub-group:
- •Implantation of a RM Pressfit vitamys Cup
- •Unilateral THA with healthy contralateral hip
- •X-ray must be analyzable
排除标准
- •Patient may not:
- •Participate simultaneously in another clinical study or documentation with other orthopaedic implants of competitors.
- •Offer no guarantee for regular follow-up controls
- •Suffer from the exclusion criteria: sepsis or malignant tumours.
- •Have an ASA Classification > 3.
- •Have a revision surgery
研究者
相似试验
招募中
4 期
A post marketing study to evaluate safety and effectiveness of Remogliflozin and Remogliflozin-Metformin Combination in treatment of Diabetes patientsCTRI/2019/11/022062Glenmark Pharmaceuticals Ltd
尚未招募
4 期
Safety and efficacy of Ayukalash on high blood pressure and cholesterol.CTRI/2024/05/067632Med Pharma CRO
已完成
4 期
A post-marketing study of the marketed product Maxtra® P syrup for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031189Zuventus Healthcare Limited200
已完成
4 期
A post-marketing study of the marketed product Maxtra® P Tablets for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031390Zuventus Healthcare Limited200
已完成
不适用
postmarketing surveillance For Investigating success in achieving clinical and functional Remission and Sustaining efficacy with Tocilizumab in BIOlogics naive RA patientsPatients with rheumatoid arthritis who have been diagnosed based on the 2010 ACR/EULAR new classification criteria for RA Patients who have no previous medical history of biological agents for RA Patients whose disease activity is DAS28>=3.2 at baselineJPRN-UMIN000006914Chugai Pharmaceutical Co. Ltd.700